Exclusive Summary

• Proven Mechanism with Key Differentiation: UB672 is an ICS/LABA/LAMA (Budesonide/Formoterol/Umeclidinium) triple-combination inhalation therapy for Asthma & COPD, offering best-in-class potential with ultra-rapid onset (1-3 mins) and lower pneumonia risk.
• Innovative Device Design: Utilizes an optimized Reservoir-type Dry Powder Inhaler (DPI) that requires no hand-lung coordination. Its internal airflow is precision-engineered to significantly increase Fine Particle Fraction (FPF) and deep lung deposition.
• Clinically De-risked: Phase I clinical trials have shown successful pharmacokinetic profiles, no drug-drug interactions (DDI) among the three components, and excellent safety/tolerability at steady state. Phase II is currently ongoing.
• Clear Competitive Edge: Compared to standard-of-care (AZ's pMDI and GSK's once-daily blister DPI), UB672 offers superior device usability, higher M3 receptor selectivity, and a twice-daily regimen that directly addresses the two most severe symptom periods of the day.

Asset Materials

Contact Us for Full Materials